SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
SEC Accession No. 0001354457-23-000656
Filing Date
2023-09-08
Accepted
2023-09-08 10:13:34
Documents
2
Confirming Copy
 

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 25-NSE  
1 primary_doc.xml 25-NSE 1109
2 nymxdelistreason.txt EX-99.25 1584
  Complete submission text file 0001354457-23-000656.txt   4424
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Subject) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 25-NSE | Act: 34 | File No.: 001-12033
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address Office of General Counsel 805 King Farm Blvd. ROCKVILLE MD 20850
Business Address One Liberty Plaza New York NY 10006 301-978-4144
Nasdaq Stock Market LLC (Filed by) CIK: 0001354457 (see all company filings)

IRS No.: 521165937 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 25-NSE